Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
61
Language
English
Published on
31/01/25
You may also be interested by these reports :
16/03/26
Amplifon has announced the acquisition of GN Store Nord’s hearing business, marking a shift towards a backward integration strategy, which deviates ...
13/03/26
In addition to a downward revision to our estimates, we have also incorporated a 30% discount to peer-based valuation metrics to account for business ...
12/03/26
We have revised our 2025 figures downward as actuals came in weaker than expected, starting with a 3.5% miss on the top line. We were overly ...
05/03/26
Elekta’s Q3 profitability exceeded consensus expectations. Organic sales growth was recorded in EMEA and APAC, while the Americas exhibited weakness. ...